Navigation Links
Novel Cancer Immunotherapy set to enter Clinical Trials

LAWRENCEBURG, Ind., April 16, 2013 /PRNewswire/ -- PDS Biotechnology Corporation today presented a summary of the company's preclinical data on its lead cancer immunotherapy PDS0101 at the World Vaccine Congress in Washington DC.  The product is based on the company's ground-breaking and proprietary Versamune™ nanotechnology vaccine platform.  PDS Biotechnology also announced that the company's Investigational New Drug (IND) application had been granted by the FDA allowing PDS0101 to be evaluated in human patients.

PDS0101 is a first-in-class immunotherapy being developed to treat cancers and diseases caused by infection with the human papillomavirus such as cervical cancer, head and neck cancer and cervical intraepithelial neoplasia.  Dr. Frank Bedu-Addo , President and CEO presented the highly promising preclinical efficacy and safety data demonstrating eradication of the tumors without any of the safety drawbacks typical of the current immunotherapy technologies.  PDS0101 is designed to prime the immune system to recruit cells of the body's own immune system to specifically recognize, target and kill the cancer cells.  PDS0101 is also designed to reduce the population of certain immune suppressive cells which prevent our immune systems from detecting and attacking the cancer cells.  "Should the preclinical results be replicated in the clinical setting, this will be a giant leap forward in the development of safe and effective cancer therapies," said Frank Bedu-Addo .

Versamune™ is a nanotechnology-based immune modulating technology which acts by a novel mechanism to prime and activate the immune system to recognize specific diseased cells and disease causing agents.   The technology is unique in its multiple-mode-of-action enabling simple and effective disease-targeting vaccines and immunotherapies to be developed.

About PDS Biotechnology Corporation

PDS Biotechnology is a privately held biotechnology company developing vaccines and immunotherapies based on the company's proprietary Versamune platform.  In addition to PDS0101, the company is also currently developing a potentially game-changing influenza vaccine which in preclinical studies has demonstrated significantly improved speed in which protection against the disease is developed.  In preclinical studies, the strength of the protective immune response was also significantly increased even at lower vaccine doses when compared to the current US licensed flu vaccine.  In June of 2012 PDS granted an exclusive license to Merck KGaA, Darmstadt, Germany for use of Versamune in 2 specific cancer vaccines.  PDS Biotechnology Corporation is headquartered in Lawrenceburg, IN.  Additional information about the company and technology may be found online at

SOURCE PDS Biotechnology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Data on SEEKs Novel Immunotherapy for HIV Published in Virology Journal
2. TransCelerate BioPharma Inc. Grows, Strengthens Novel Effort to Accelerate Drug Development
3. NewGen Therapeutics Presents Data on NT-113, A Novel Pan-ErbB Inhibitor, at American Association of Cancer Research
4. scPharmaceuticals LLC Announces Strategic Partnership with Sensile Medical to Develop Novel Heart Failure Treatment Aimed to Reduce Readmission Rates
5. X-BODY Announces Multi-Million Dollar Development Alliance With Jiangsu Hengrui Medicine Co., Ltd., A Leading Pharmaceutical Company In China, To Develop Novel Therapeutic Antibodies For AMD
6. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
7. NeuroVive Acquires Highly Potent, Novel Cyclophilin Inhibitors From Biotica
8. A Novel Oral Anticoagulant is Planned to be Developed for Patients with Prosthetic Heart Valves or Chronic Renal Dysfunction
9. Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
10. Alzheimers Drug Discovery Foundation Awards Grant To CohBar to Develop A Novel Peptide Therapeutic For Alzheimers Disease
11. West Announces the Commercial Introduction of a Novel Intradermal Adapter for Disposable Syringes
Post Your Comments:
(Date:11/29/2015)... 2015 CIVCO Medical Solutions will demonstrate ... Radiological Society of North America ... November 29 – December 4, 2015. The ... customers unrivaled versatility, enhanced user experience and deliver ... --> --> ...
(Date:11/27/2015)... Nov. 27, 2015  Lannett Company, Inc. (NYSE: ... completed the acquisition of Kremers Urban Pharmaceuticals Inc. ... global biopharmaceuticals company UCB S.A. (Euronext: UCB). ... has acquired KU from UCB for total consideration ... including a customary working capital adjustment, a deduction ...
(Date:11/26/2015)... Carolina , 26 november 2015 /PRNewswire/ ... (AAIPharma/CML) kondigt de geplande investering aan van ... van de laboratoria en het mondiale hoofdkantoor ... De uitbreiding zal resulteren in extra kantoorruimte ... voldaan aan de groeiende behoeften van de ...
Breaking Medicine Technology:
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... ... exchange technology and teleradiology services, has added Chris Hafey and Claude Hooton to ... at the Radiological Society of North America (RSNA) 2015 Annual Meeting and continues ...
(Date:11/28/2015)... ... ... Trying to relax on a couch can actually be uncomfortable, so an ... due to personal experience with a bad back," he said. , This easy-to-use, versatile ... as increases support. It also makes it easier to eat, do other activities and ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back again with ... from, the possibilities are endless. Users have full control over angle of view, speed ... effects, users are sure to get heads to turn. , ProPanel: Pulse offers fully ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published November ... meeting in Washington D.C. revolved around the fact that proper dental care, both at-home ... stressed the link between periodontal disease (more commonly referred to as gum disease) and ...
(Date:11/27/2015)... ... 2015 , ... According to an article published November 15th by ... handling security in light of the recent terrorist attacks in Paris, other cities are ... an attack from reaching U.S. soil. Especially around special events that may be high-profile ...
Breaking Medicine News(10 mins):